Bactericidal Activity of Rifampin-Amikacin against Mycobacterium ulcerans in Mice

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2002-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.46.10.3193-3196.2002PMID 12234844PMCID PMC128793
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activities of New Macrolides and Fluoroquinolones against Mycobacterium ulcerans Infection in Mice

  2001cited by this paper
• Activities of Several Antimicrobials againstMycobacterium ulcerans Infection in Mice

  2000cited by this paper
• Mycobacterium ulcerans infection.

  1999cited by this paper
• Partial purification and characterization of biological effects of a lipid toxin produced by Mycobacterium ulcerans.

  1998cited by this paper
• Immunology of leprosy.

  1993cited by this paper
• Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice

  1993cited by this paper
• Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice

  1992cited by this paper
• Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice

  1991cited by this paper
• Aminoglycosides

  1990cited by this paper
• Principles and practice of infectious disease

  1990cited by this paper
• The immunology of leprosy.

  1983cited by this paper
• Statistical analysis of results obtained by two methods for testing drug activity against Mycobacterium leprae.

  1982cited by this paper
• Statistical analysis of results obtained by two methods for testing drug activity against Mycobacterium leprae.

  1982cited by this paper
• Principles and practice of infectious diseases. Vols 1 and 2.

  1979cited by this paper
• The "proportional bactericidal test": a method for assessing bactericidal activity in drugs against Mycobacterium leprae in mice.

  1978cited by this paper
• The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy.

  1978cited by this paper
• A method for counting acid-fast bacteria.

  1968influential reference
• A kinetic method for the study of drugs against Mycobacterium leprae in mice

  1967cited by this paper
• [TREATMENT OF EXPERIMENTAL INFECTION BY MYCOBACTERIUM ULCERANS AND MYCOBACTERIUM BALNEI IN MICE].

  1965cited by this paper
• THE EXPERIMENTAL DISEASE THAT FOLLOWS THE INJECTION OF HUMAN LEPROSY BACILLI INTO FOOT-PADS OF MICE

  1960cited by this paper
• Mycobacterium ulcerans infections; response to chemotherapy in mice.

  1957cited by this paper
• The pathogenic behavior of Mycobacterium ulcerans and Mycobacterium balnei in the mouse and the developing chick embryo.

  1956cited by this paper
• Antibacterial chemotherapy.

  1949cited by this paper

• L’ulcère de Buruli, une maladie tropicale négligée due à Mycobacterium ulcerans

  2023cites this paper
• Detection of Mycolactone by Thin Layer Chromatography.

  2022cites this paper
• Drug Efficacy Testing in the Mouse Footpad Model of Buruli Ulcer.

  2022cites this paper
• Ultrashort treatment with telacebec alone and with companion drugs in immunocompetent and immunosuppressed mouse footpad models of Buruli ulcer

  2021influential citation
• The Many Hosts of Mycobacteria 8 (MHM8): A conference report.

  2020cites this paper
• Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model

  2020cites this paper
• Pharmacologic management of Mycobacterium ulcerans infection

  2020cites this paper
• Mycobactérioses cutanées dues à Mycobacterium ulcerans, Mycobacterium marinum, Mycobacterium abscessus, Mycobacterium chelonae et autres mycobactéries non tuberculeuses

  2020cites this paper
• Ultra-short-course and intermittent TB47-containing oral regimens produce stable cure against Buruli ulcer in a murine model and prevent the emergence of resistance for Mycobacterium ulcerans

  2020cites this paper
• Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses

  2020influential citation
• Q203 containing fully intermittent oral regimens exhibited high sterilizing activity against Mycobacterium ulcerans in mice

  2019cites this paper
• The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model

  2019cites this paper
• In Vivo Imaging of Bioluminescent Mycobacterium ulcerans: A Tool to Refine the Murine Buruli Ulcer Tail Model.

  2019cites this paper
• Recombinant Antibodies against Mycolactone

  2019cites this paper
• Buruli Ulcer in Animals and Experimental Infection Models

  2019cites this paper
• Laboratory Diagnosis of Buruli Ulcer: Challenges and Future Perspectives

  2019cites this paper
• Antimicrobial Treatment of Mycobacterium ulcerans Infection

  2019cites this paper
• Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay

  2019cites this paper
• Bioluminscent Mycobacterium ulcerans, a tool to study host-pathogen interactions in a murine tail model of Buruli ulcer

  2018cites this paper
• Tuberculous and tuberculoid lesions in free living small terrestrial mammals and the risk of infection to humans and animals: a review

  2018cites this paper
• Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer

  2018cites this paper
• Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer

  2018cites this paper
• High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease

  2018cites this paper
• Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer

  2018cites this paper
• A protocol for culturing environmental strains of the Buruli ulcer agent, Mycobacterium ulcerans

  2018cites this paper
• Effectiveness of purified methylene blue in an experimental model of Mycobacterium ulcerans infection.

  2017cites this paper
• Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans

  2017cites this paper
• Epidemiology and Drug Resistance of Non Tuberculous Mycobacteria in India: a Mini Review

  2017cites this paper
• In Vitro Susceptibility of Mycobacterium ulcerans Isolates to Selected Antimicrobials

  2017cites this paper
• Buruli Ulcer: Case Study of a Neglected Tropical Disease

  2017cites this paper
• Modeling the Transmission and Prevention of Infectious Disease

  2017cites this paper
• Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice

  2016cites this paper
• FVB/N Mice Spontaneously Heal Ulcerative Lesions Induced by Mycobacterium ulcerans and Switch M. ulcerans into a Low Mycolactone Producer

  2016cites this paper
• Experimental Survival of Mycobacterium ulcerans in Watery Soil, a Potential Source of Buruli Ulcer.

  2016cites this paper
• Genotyping and Treatment of Secondary Bacterial Infections among Buruli Ulcer Patients in the Amansie Central District of Ghana

  2016cites this paper
• Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease

  2015cites this paper
• The Buruli Ulcer

  2015cites this paper
• Spontaneous Healing of Mycobacterium ulcerans Lesions in the Guinea Pig Model

  2015cites this paper
• Methods used in preclinical assessment of anti-Buruli ulcer agents: A global perspective.

  2015cites this paper
• Clinical and Bacteriological Efficacy of Rifampin-Streptomycin Combination for Two Weeks followed by Rifampin and Clarithromycin for Six Weeks for Treatment of Mycobacterium ulcerans Disease

  2014cites this paper
• Accelerated Detection of Mycolactone Production and Response to Antibiotic Treatment in a Mouse Model of Mycobacterium ulcerans Disease

  2014cites this paper
• Microbiological, Histological, Immunological, and Toxin Response to Antibiotic Treatment in the Mouse Model of Mycobacterium ulcerans Disease

  2013cites this paper
• The impact of climate warming on the interaction of aphid wheat pests Rhopaloshipum padi and R. maidis

  2013cites this paper
• Development Of Molecular Epidemiological Tools For Better Understanding And Control Of Buruli Ulcer

  2013cites this paper
• Evaluating and Improving Microbiological Methods for the Diagnosis of Buruli Ulcer Disease

  2013cites this paper
• Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review

  2013cites this paper
• Bactericidal Activity Does Not Predict Sterilizing Activity: The Case of Rifapentine in the Murine Model of Mycobacterium ulcerans Disease

  2013cites this paper
• TREATING BURULI ULCER A REVIEW OF PROSPECTS FOR EXISTING ANTIBIOTICS AND NEW THERAPEUTICS

  2013influential citation
• Clinical and Bacteriological Efficacy of Rifampin-Streptomycin Combination for Two Weeks followed by Rifampin and Clarithromycin for Six Weeks for Treatment of Mycobacterium ulcerans Disease

  2013cites this paper
• Local and Regional Re-Establishment of Cellular Immunity during Curative Antibiotherapy of Murine Mycobacterium ulcerans Infection

  2012influential citation
• Corticosteroid-Induced Immunosuppression Ultimately Does Not Compromise the Efficacy of Antibiotherapy in Murine Mycobacterium ulcerans Infection

  2012cites this paper
• Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

  2011cites this paper
• Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination against Mycobacterium ulcerans Disease in Mice

  2011cites this paper
• BCG-Mediated Protection against Mycobacterium ulcerans Infection in the Mouse

  2011cites this paper
• All-Oral Antibiotic Treatment for Buruli Ulcer: A Report of Four Patients

  2010cites this paper
• Neglected diseases caused by bacterial infections.

  2010cites this paper
• [Buruli ulcer or Mycobacterium ulcerans infection].

  2010cites this paper
• Pharmacokinetics of Rifampin and Clarithromycin in Patients Treated for Mycobacterium ulcerans Infection

  2010cites this paper
• Clinical Efficacy of Combination of Rifampin and Streptomycin for Treatment of Mycobacterium ulcerans Disease

  2010cites this paper
• Understanding Buruli Ulcer (Mycobacterium ulcerans Disease)

  2010cites this paper
• Current treatment of atypical mycobacteriosis

  2009cites this paper
• Subcutaneous injection of Mycobacterium ulcerans causes necrosis, chronic inflammatory response and fibrosis in skeletal muscle.

  2008cites this paper
• Aspects of tropical ulcerating diseases

  2008cites this paper
• Pharmacokinetics of Rifampicin and Clarithromycin in Patients Treated for Mycobacterium ulcerans Infection in Ghana

  2008cites this paper
• Imported Tropical Infectious Ulcers in Travelers

  2008cites this paper
• Community‐based study on knowledge, attitude and practice on the mode of transmission, prevention and treatment of the Buruli ulcer in Ga West District, Ghana

  2007cites this paper
• Consensus recommendations for the diagnosis, treatment and control of Mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia

  2007cites this paper
• BEWARE THE BURULI ULCER

  2007cites this paper
• Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer (Mycobacterium ulcerans Disease)

  2007cites this paper
• Clinical and Histopathological Presentation of Buruli Ulcer in Experimentally Infected Grasscutters (Thryonomys swinderianus)

  2006cites this paper
• Probable Cause of Painlessness in Buruli Ulcer

  2006cites this paper
• Bacteriological and immunological studies towards effective control of Mycobacterium ulcerans disease (Buruli ulcer)

  2006cites this paper
• In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans

  2006cites this paper
• Mycobacterium ulcerans infection: control, diagnosis, and treatment.

  2006cites this paper
• Curing Mycobacterium ulcerans Infection in Mice with a Combination of Rifampin-Streptomycin or Rifampin-Amikacin

  2006cites this paper
• Nerve damage in Mycobacterium ulcerans-infected mice: probable cause of painlessness in buruli ulcer.

  2006cites this paper
• Development of new molecular genetic tools to study "Mycobacterium ulcerans" infection (Buruli ulcer)

  2005cites this paper
• Buruli ulcer

  2005cites this paper
• Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans

  2005influential citation
• Buruli Ulcer Recurrence, Benin

  2005cites this paper
• Infections due to non-tuberculous mycobacteria (NTM).

  2004cites this paper
• [Diagnosis of Mycobacterium ulcerans infections in French Guiana].

  2004cites this paper
• Nontuberculous Mycobacterial Infections: A Clinical Review

  2004cites this paper
• Diagnostic de l’infection à Mycobacterium ulcerans en Guyane française

  2004cites this paper
• [Comparison of inhibitory effect of rifalazil and rifampicin against Mycobacterium ulcerans infection induced in mice].

  2004cites this paper
• Immunoglobulin M Antibody Responses to Mycobacterium ulcerans Allow Discrimination between Cases of Active Buruli Ulcer Disease and Matched Family Controls in Areas Where the Disease Is Endemic

  2004cites this paper
• Mycolactones and Mycobacterium ulcerans disease.

  2003cites this paper
• Emerging aspects of Buruli ulcer

  2003cites this paper
• Les tréponématoses endémiques et l'ulcère de Buruli : deux ostéomyélites exotiques d'actualité

  2003cites this paper
• Development and Application of Real-Time PCR Assay for Quantification of Mycobacterium ulcerans DNA

  2003cites this paper